Area of research
Public Health, Environmental and Occupational Health · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Childhood Cancer Survivors' Quality of Life, Acute Myeloid Leukemia Research, and Chronic Myeloid Leukemia Treatments.
Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study.
Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia.
Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST.
Supplementary Figure 2 from Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia
Data from Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia
Supplementary Table 1 from Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia
Supplementary Figure 1 from Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia
Supplemental Nutrition Assistance Program participation gaps within a pediatric leukemia clinical trial cohort.
The impact of comparative genomic hybridization/single-nucleotide polymorphism microarray in risk stratification of pediatric acute lymphoblastic leukemia.
Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/<i>KMT2A</i> Rearrangements in a Modern Therapy Era: A Retrospective International Study.
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis
A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis.
Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium.
<i>ETV6</i> fusions from insertions of exons 3-5 in pediatric hematologic malignancies.
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/<i>KMT2A</i>Rearrangements in a Modern Therapy Era: A Retrospective International Study
Recombinant <i>Erwinia</i> asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (study T2008‐002 NECTAR)
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Feasibility of oncology clinical trial-embedded evaluation of social determinants of health.
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.